文献速递痛风与晶体性关节病

痛风患者启动降尿酸治疗时非甾体抗炎药与秋水仙碱的心血管安全性比较:目标试验模拟

Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial Emulations.
PubMed 文献 · Arthritis Rheumatol · 2025-07-29

该目标试验模拟研究在18,120例启动别嘌醇的痛风成人中比较非甾体抗炎药与秋水仙碱用于痛风发作预防的心血管安全性。非甾体抗炎药组主要不良心血管事件和心血管死亡发生率均高于秋水仙碱组,HR分别为1.56和2.50。与无预防相比,非甾体抗炎药与主要不良心血管事件和心肌梗死风险升高相关。

要点

  • 非甾体抗炎药组主要不良心血管事件发生率较秋水仙碱组高,率差38.8/1000人年,HR 1.56。
  • 非甾体抗炎药组心血管死亡发生率较秋水仙碱组高,率差10.9/1000人年,HR 2.50。
  • 与无预防相比,非甾体抗炎药与主要不良心血管事件(HR 1.50)和心肌梗死(HR 1.93)风险升高相关。

核心结论

  • 在启动别嘌醇的痛风患者中,非甾体抗炎药预防与主要不良心血管事件风险高于秋水仙碱或无预防相关,作者认为应避免使用非甾体抗炎药进行痛风发作预防。

研究设计与样本

  • 采用目标试验模拟框架的序贯倾向评分匹配新使用者比较效果研究。
  • 纳入18,120例启动别嘌醇并处方非甾体抗炎药或秋水仙碱进行痛风发作预防的痛风成人(83.5%男性,平均年龄60.9岁)。
  • 敏感性分析采用逆概率治疗加权。

主要发现

  • 非甾体抗炎药组主要不良心血管事件发生率较秋水仙碱组高,率差38.8(95%CI 15.4-62.2)/1000人年,HR 1.56(95%CI 1.11-2.17)。
  • 非甾体抗炎药组心血管死亡发生率较秋水仙碱组高,率差10.9(95%CI 0.7-21.1)/1000人年,HR 2.50(95%CI 1.14-5.26)。
  • 逆概率治疗加权后结果相似。
  • 与无预防相比,非甾体抗炎药与主要不良心血管事件风险升高相关,HR 1.50(95%CI 1.17-1.91)。
  • 与无预防相比,非甾体抗炎药与心肌梗死风险升高相关,HR 1.93(95%CI 1.35-2.75)。

临床怎么用

  • 作者认为,应避免使用非甾体抗炎药进行痛风发作预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Among patients with gout, nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used despite scarce safety data in this specific population. Therefore, we quantified the comparative cardiovascular safety of NSAIDs versus colchicine among patients with gout starting allopurinol. METHODS: We conducted a sequential, propensity score-matched, new-user comparative effectiveness study using the target trial emulation framework to compare the risk of major adverse cardiovascular events (MACE; composite of myocardial infarction [MI], stroke, or cardiovascular death) among patients with gout started on allopurinol who were prescribed NSAIDs or colchicine for gout flare prophylaxis. A sensitivity analysis employed inverse probability of treatment weighting (IPTW). Secondarily, we examined the risk of MACE with colchicine or NSAIDs versus no prophylaxis. RESULTS: Among 18,120 propensity score-matched adults with gout starting allopurinol with NSAIDs or colchicine (83.5% male, mean age 60.9 years), the incidence of MACE and cardiovascular death were higher among NSAID users compared to colchicine users, with rate differences of 38.8 (95% confidence interval [CI] 15.4-62.2) and 10.9 (95% CI 0.7-21.1) per 1,000 person-years, respectively, and hazard ratios (HRs) of 1.56 (95% CI 1.11-2.17) and 2.50 (95% CI 1.14-5.26), respectively. Results were similar when IPTW was applied. Compared to no prophylaxis, NSAID use was associated with a higher risk of MACE and MI, with HRs of 1.50 (95% CI 1.17-1.91) and 1.93 (95% CI 1.35-2.75), respectively. CONCLUSION: In these target trial emulations of patients with gout starting allopurinol, NSAID prophylaxis was associated with a higher risk of MACE than colchicine or no prophylaxis, suggesting the avoidance of NSAID for gout flare prophylaxis.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Yokose C, McCormick N, Lu N, et al. Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial Emulations. Arthritis Rheumatol. 2025. PMID: 40415645. doi:10.1002/art.43259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。